Phaseline

Companies › Claris Biotherapeutics

Claris Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CSB-001 Ophthalmic Solution 0.1%
Human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
HGFPhase 1Corneal Scar; Limbal Stem Cell DeficiencyJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06257355CSB-001 Ophthalmic Solution 0.1%Phase 1Corneal ScarOphthalmologyJun 2027
NCT06452316CSB-001 Ophthalmic Solution 0.1%Phase 1Limbal Stem Cell DeficiencyOphthalmologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

HGF (1)

Companies with the same targets

AVEO Pharmaceuticals Kringle Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.